| scholarly article | Q13442814 |
| P50 | author | Kenneth W Mahaffey | Q63101609 |
| Glenn Chertow | Q87653339 | ||
| Sharon M Moe | Q91339340 | ||
| Tilman B Drueke | Q47097110 | ||
| P2093 | author name string | Patrick S Parfrey | |
| David C Wheeler | |||
| Jürgen Floege | |||
| Charles A Herzog | |||
| Tilman B Drüeke | |||
| Bastian Dehmel | |||
| William G Goodman | |||
| Gerard M London | |||
| Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators | |||
| Geoffrey A Block | |||
| Ricardo Correa-Rotter | |||
| Safa Abdalla | |||
| P2860 | cites work | Risk factors for hip fracture among patients with end-stage renal disease | Q73108274 |
| Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone | Q73235636 | ||
| Increased risk of hip fracture among patients with end-stage renal disease | Q73969374 | ||
| NPS R-568 halts or reverses osteitis fibrosa in uremic rats | Q74165172 | ||
| Risk factors for vertebral fractures in renal osteodystrophy | Q74451547 | ||
| Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism | Q79103377 | ||
| Relationship between moderate to severe kidney disease and hip fracture in the United States | Q79150009 | ||
| Fracture risk after parathyroidectomy among chronic hemodialysis patients | Q80624484 | ||
| Determinants of prevalent vertebral fractures and progressive bone loss in long-term hemodialysis patients | Q83245882 | ||
| Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease | Q83598718 | ||
| Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study | Q84302487 | ||
| Increased bone fractures among elderly United States hemodialysis patients | Q86062532 | ||
| Trends in hip fracture rates in US hemodialysis patients, 1993-2010 | Q86693755 | ||
| Cinacalcet for cardiovascular disease in patients undergoing dialysis | Q86746292 | ||
| PTH--a particularly tricky hormone: why measure it at all in kidney patients? | Q26864011 | ||
| Skeletal effects of zoledronic acid in an animal model of chronic kidney disease | Q33779709 | ||
| Chronic kidney disease and bone fracture: a growing concern | Q34069692 | ||
| Misconceptions (2): turnover is always higher in cancellous than in cortical bone | Q34674477 | ||
| Discriminants of prevalent fractures in chronic kidney disease | Q35142758 | ||
| Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. | Q35635751 | ||
| Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States | Q37065632 | ||
| Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients | Q37119913 | ||
| A structural approach to skeletal fragility in chronic kidney disease | Q37250450 | ||
| Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. | Q37492890 | ||
| High rates of death and hospitalization follow bone fracture among hemodialysis patients | Q37542005 | ||
| Impaired muscle strength is associated with fractures in hemodialysis patients | Q38509782 | ||
| The hyperparathyroidism of chronic renal failure: A disorder of growth | Q41521915 | ||
| Overexpression of Runx2 and MKP-1 stimulates transdifferentiation of 3T3-L1 preadipocytes into bone-forming osteoblasts in vitro | Q42815602 | ||
| Increased osteocyte death and mineralization inside bone after parathyroidectomy in patients with secondary hyperparathyroidism | Q43055101 | ||
| Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor | Q43242533 | ||
| Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease | Q43470405 | ||
| The association of radiographically detected vertebral fractures with back pain and function: a prospective study | Q43602714 | ||
| Risk factors for hip fracture in hemodialysis patients | Q44095995 | ||
| Incidence and risk factors for hip fractures in dialysis patients | Q44635041 | ||
| The three-year incidence of fracture in chronic kidney disease. | Q44741994 | ||
| Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis | Q44835152 | ||
| Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis | Q44871721 | ||
| Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? | Q45010758 | ||
| The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial | Q45073262 | ||
| Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview | Q45239493 | ||
| Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial | Q47861164 | ||
| Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 | ||
| Towards a rational combination therapy of cystic fibrosis: How cystamine restores the stability of mutant CFTR. | Q50878459 | ||
| Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. | Q50920633 | ||
| Increased risk of hip fracture among Japanese hemodialysis patients. | Q51282990 | ||
| Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. | Q51789429 | ||
| Cortical pQCT measures are associated with fractures in dialysis patients. | Q53543744 | ||
| PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. | Q53607251 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone fracture | Q68833 |
| hemodialysis | Q391744 | ||
| Osteodystrophy | Q3357466 | ||
| hemodialysis patient | Q126109077 | ||
| ckd | Q29714295 | ||
| P304 | page(s) | 1466-1475 | |
| P577 | publication date | 2014-12-11 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial | |
| P478 | volume | 26 |
| Q48118406 | A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. |
| Q30313255 | A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine |
| Q64090390 | An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism |
| Q36166690 | Analysis of the kinetics of the parathyroid hormone, and of associated patient outcomes, in a cohort of haemodialysis patients |
| Q38579166 | Bone Disorders in Chronic Kidney Disease: An Update in Diagnosis and Management |
| Q36965098 | Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis |
| Q90305128 | Bone fragility in patients with chronic kidney diseases |
| Q38576402 | Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures |
| Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
| Q43475954 | Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis |
| Q51736986 | Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. |
| Q37639872 | Chronic kidney disease and fragility fracture |
| Q38565049 | Cinacalcet and Clinical Outcomes in Dialysis |
| Q93048783 | Cinacalcet attenuated bone loss via inhibiting parathyroid hormone-induced endothelial-to-adipocyte transition in chronic kidney disease rats |
| Q47549937 | Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism |
| Q97545305 | Clinical and Healthcare Utilization Outcomes of Parathyroidectomy in CKD and Dialysis Patients |
| Q36432849 | Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. |
| Q38714295 | Declining Rates of Hip Fracture in End-stage Renal Disease: Analysis from the 2003-2011 Nationwide Inpatient Sample |
| Q55476982 | Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). |
| Q50026683 | Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism |
| Q37638757 | Efficacy of low-dose cinacalcet on alternate days for the treatment of secondary hyperparathyroidism in hemodialysis patients: a single-center study |
| Q39170853 | Etelcalcetide for the treatment of secondary hyperparathyroidism. |
| Q39225909 | Evaluation of fracture risk in chronic kidney disease. |
| Q88421208 | Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease |
| Q41890926 | FGF23 in chronic kidney disease: are we lost in translation? |
| Q44114622 | Fractures in Patients with CKD: Time for Action |
| Q38828618 | Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification |
| Q36687041 | Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis |
| Q87900128 | Management of Osteoporosis in CKD |
| Q38775426 | Management of secondary hyperparathyroidism: how and why? |
| Q30234751 | Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. |
| Q92104995 | New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology |
| Q49166621 | Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes |
| Q30235173 | Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. |
| Q39014553 | Osteoporosis in patients with diabetes after kidney transplantation |
| Q36425115 | Pathophysiology of the chronic kidney disease-mineral bone disorder |
| Q59126536 | Rethinking Bone Disease in Kidney Disease |
| Q40996542 | Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic |
| Q39220825 | Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. |
| Q39101623 | The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology |
| Q64236654 | Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison |
| Q49375971 | Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors |
| Q57796694 | Updates in CKD-Associated Osteoporosis |
| Q39345412 | Uremic Toxicity and Bone in CKD. |
Search more.